Abstract
Postnatal skeletogenesis is a highly regulated process that subpopulations of bone marrow stem cells differentiate into mature skeletal tissues to maintain and repair the postnatal skeletons. Based on their skeletogenic capacity, purified bone marrow stem cells have been used to repair and replace damaged skeletal tissues in recent years. In the meantime, significant effort has been devoted to unveil the nature and function of the “skeletogenic” precursors in vivo. In this review, we summarized our current understanding of the identification and fate-mapping of the stem cells contributing to postnatal skeletogenesis in the mouse bone marrow.
Keywords: Fate-mapping, mesenchymal stem cells, multipotency, osteochondroreticular stem cells, postnatal skeletogenesis, transplantation.
Current Stem Cell Research & Therapy
Title:Stem cells contributing to postnatal skeletogenesis in the mouse bone marrow
Volume: 10 Issue: 5
Author(s): Peng Deng, Xiaoping Xu and Qianming Chen
Affiliation:
Keywords: Fate-mapping, mesenchymal stem cells, multipotency, osteochondroreticular stem cells, postnatal skeletogenesis, transplantation.
Abstract: Postnatal skeletogenesis is a highly regulated process that subpopulations of bone marrow stem cells differentiate into mature skeletal tissues to maintain and repair the postnatal skeletons. Based on their skeletogenic capacity, purified bone marrow stem cells have been used to repair and replace damaged skeletal tissues in recent years. In the meantime, significant effort has been devoted to unveil the nature and function of the “skeletogenic” precursors in vivo. In this review, we summarized our current understanding of the identification and fate-mapping of the stem cells contributing to postnatal skeletogenesis in the mouse bone marrow.
Export Options
About this article
Cite this article as:
Deng Peng, Xu Xiaoping and Chen Qianming, Stem cells contributing to postnatal skeletogenesis in the mouse bone marrow, Current Stem Cell Research & Therapy 2015; 10 (5) . https://dx.doi.org/10.2174/1574888X10666150519093626
DOI https://dx.doi.org/10.2174/1574888X10666150519093626 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells
Anti-Cancer Agents in Medicinal Chemistry Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Recent Applications of Artificial Intelligence in Early Cancer Detection
Current Medicinal Chemistry Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design